TRVI - NASDAQ

Trevi Therapeutics, Inc.

TRVI·NASDAQ

$14.00

+4.1%

HealthcareBiotechnology

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.99B

EPS-0.2900

P/E Ratio-48.28

Earnings Date08/06/2026

trvi

Other Non-Current Assets

Last Annual Value

928.00K

3-Year CAGR

65%

5-Year CAGR

12%

10-Year CAGR

54%

Adjust for Inflation

Trevi Therapeutics, Inc. Competitors Analysis of Other Non-Current Assets

TRVI · NASDAQ

Company	Other Non-Current Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Trevi Therapeutics, Inc. NASDAQ:TRVI	928.00K	46.2%	22.7%	54.5%
Ardelyx, Inc. NASDAQ:ARDX	112.31M	35.8%	150.0%	94.1%
Zenas BioPharma, Inc. NASDAQ:ZBIO	13.81M	23.3%	N/A	N/A
ORIC Pharmaceuticals, Inc. NASDAQ:ORIC	98.00K	17.1%	-62.0%	N/A
Novavax, Inc. NASDAQ:NVAX	17.08M	-21.4%	-21.3%	12.2%
Precigen, Inc. NASDAQ:PGEN	908.00K	2.4%	-54.4%	-13.1%
Tourmaline Bio, Inc. NASDAQ:TRML	3.26M	49.6%	99.2%	N/A
Terns Pharmaceuticals, Inc. NASDAQ:TERN	0.00	N/A	N/A	N/A
Upstream Bio, Inc. NASDAQ:UPB	194.00K	N/A	N/A	N/A

Trevi Therapeutics, Inc. Fair Value Envelope

TRVI · NASDAQ

Our analysis suggests that TRVI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $14, this represents a potential HIDDEN relative to our calculated worth for Trevi Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $14

Related Guides

Blog Categories

Continue your TRVI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.